m+Medelevator.RU
← Поиск публикаций
Military medicine · 2026

TO-207 Mitigates Radiation-Induced Hematopoietic Injury in a Murine Model of Lethal Total-Body Irradiation.

СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Cui Wanchang, Hull Lisa, Rothstein Asher, Wang Li, Lin Bin, Zhai Min, Xiao Mang

Аннотация

INTRODUCTION: Ionizing radiation exposure can cause acute radiation syndrome (ARS) with life-threatening multi-organ damage. Although several hematopoietic growth factors are FDA-approved as radiation countermeasures, alternative strategies that target inflammatory mechanisms remain urgently needed. TO-207, formerly known as JTE-607, is a selective multi-cytokine inhibitor that suppresses pro-inflammatory cytokine secretion in human monocytes and macrophages. TO-207 represents a mechanistically distinct radiation mitigator; however, whether it suppresses the acute post-irradiation cytokine surge in vivo has not yet been directly demonstrated and remains to be confirmed in future studies.

MATERIALS AND METHODS: Male CD2F1 mice were exposed to lethal total-body irradiation (TBI, 9.0 Gy, LD70/30). Mice received TO-207 (100 mg/kg, s.c.) or vehicle once daily for 3 consecutive days, starting at 24 hours after irradiation. Outcomes included 30-day survival, peripheral blood recovery, bone marrow clonogenic capacity, and serum cytokine profiling.

RESULTS: TO-207 treatment improved survival to 65% compared to 45% in vehicle controls. Hematopoietic recovery was enhanced, with significant increases in colony-forming unit-granulocyte/macrophage (CFU-GM) and higher circulating monocyte counts on day 30. Serum cytokine profiling on day 30 revealed that 3 of 44 cytokines (G-CSF, KC, TNF-α) showed nominally significant differences between groups; however, none remained significant after Benjamini-Hochberg correction for multiple comparisons. These day-30 cytokine observations are exploratory and reflect patterns of altered immune reconstitution rather than direct evidence of acute cytokine suppression.

CONCLUSIONS: TO-207 significantly mitigated hematopoietic injury and improved survival when administered 24 hours after lethal irradiation. These findings highlight TO-207 as a promising candidate for development as a medical countermeasure for ARS. Future studies incorporating early cytokine time points, dose optimization, and both sexes are needed to substantiate the mechanistic hypothesis and maximize translational impact.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты